Due to PD-1′s inhibiting role on anti-tumor immune responses, we wanted to investigate whether demethylation of the PD-1 promoter in T cells and PBMNCs during 5-aza treatment is correlated to the clinical response. Here, PDCD1 is linked to neoplasm.